Journal: Nature communications

Article Title: Multiple structures of RNA polymerase II isolated from human nuclei by ChIP-CryoEM analysis.

doi: 10.1038/s41467-025-59580-x

Figure Lengend Snippet: Fig. 2 | Details of the EC-SPT4/5-ELOF1-SPT6 structure. a Domain architectures of the elongation factors. The known domains are indicated. b Close-up view of ELOF1 (purple). c Close-up view around the upstream DNA. d Close-up view of the SPT5 KOW2, KOW3, KOWx, and KOW4 domains. Each KOW domain is indicated with dotted circles. SPT6 is omitted for clarity. e Close-up view of the KOW5 domain. f The SPT6-SPT5 KOW3-RPB4/7 stalk interaction. g The SPT5 KOW1-SPT6

Article Snippet: Themembraneswerewashedwith TBS-T (20mMTris-HCl (pH 7.5), 137mM NaCl, and 0.1% Tween-20) three times and then incubated overnight with anti-FLAG M2 antibody (Sigma # F3165, 1:3000), anti-SPT5 antibody (Proteintech#16511-1-AP, 1:1000), antiSPT6 antibody (Cell Signaling #15616, 1:2000), anti-PAF1 antibody (Cell Signaling #12883, 1:300), anti-RTF1 antibody (Proteintech #12170-1-AP, 1:1000), anti-MED17 antibody (Proteintech#11505-1-AP, 1:2000), or anti-XPB antibody (Cell Signaling #8746, 1:300) in Can Get Signal Immunoreaction Enhancer Solution 1 (TOYOBO #NKB-101).

Techniques:

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Expression of SLC6A8 in lung cancer (A) Expression of SLCA8 in pan-cancer *P-value < 0.05; **P-value < 0.01; ***P-value < 0.001. (B) Unpaired differential expression and (C) paired differential expression of SLC6A8 in NSCLC in TCGA database. (D) Gene alteration and copy number (E) analysis of SLCA8 in NSCLC in the eBioPortal online database. ns, no significance.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Expressing, Quantitative Proteomics

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Immunohistochemical staining and quantitative analysis of SLC6A8 expression in NSCLC. (E) Paired differential analysis of SLC6A8 in IMA1 in NSCLC. (A) LUAD paraneoplastic tissue. (B) LUAD tissue (C) LUSC paraneoplastic tissue (D) LUSC tissue (I) Unpaired differential analysis of SLC6A8 in TMA2 in NSCLC (F) Normal tissue (G) LUAD tissue (H) LUSC tissue (J) Survival analysis of SLC6A8 in TMA2 in NSCLC.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Immunohistochemical staining, Staining, Expressing

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Correlation of SLC6A8 expression with clinicopathological characteristics of NSCLC.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Construction of the lncRNA-miRNA-mRNA triple regulatory network for SLC6A8 overexpression in NSCLC. (A) Starbase database of miRNAs targeting binding to SLC6A 8 in NSCLC (B, C) Targeted miRNAs associated with SLC6A8 expression in a triple-regulatory network (cor<-0.3, P-value < 0.001, logFC<0. diffP-value < 0.05 ) (D) Starbase database of IncRNAs targeting binding to hsa-miR-26a-5p in NSCLC. (E) The ceRNA regulatory network of SLC6A8 overt expression in NSCLC.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Over Expression, Binding Assay, Expressing

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Targeted lncRNAs in the ceRNA network associated with hsa-miR-26a-5p and SLC6A8 expression.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Expressing

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Prognostic ceRNA regulatory network associated with SLC6A8 overexpression in NSCLC (A) Prognostic miRNAs associated with SLC6A8 overexpression in NSCLC (B) Prognostic IncRNAs associated with SLC648 overexpression in NSCLC (C) . Localization of prognostic IncRNAs in NSCLC cells (D) . The ceRNA network regulating SLC6A8 overexpression and prognosis in NSCLC (E) . The ceRNA network regulating SLC6A 8 overexpression and poor prognosis in NSCLC (F) Base pairing between Al 513318.2/hsa-miR-26a-5p and SLC6A8 /has-miR-26a-5p in Starbase online database.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Over Expression

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Methylation sites associated with SLC6A8 expression in NSCLC Methylation levels associated with SLC6A8 expression in LUAD (A) and LUSC (B) compared to normal tissues. Methylation regulatory sites associated with SLC6A8 expression in LUAD (C) and LUSC (D) . (r<-0.2; *P-value < 0.05; **P-value < 0.01; ***P-value < 0.001).

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Methylation, Expressing

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Correlation analysis of SLC6A8 expression and immune cell surface marker genes.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Expressing, Marker

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Immunological correlation analysis of SLC6A8 in NSCLC (A) Differential analysis of immunomodulators between high and low SLC6A8 expression groups in NSCLC (B) Prognostic analysis of immunomodulators associated with SLC6A8 in NSCLC (C, D) SLC6A8 -related immune prognostic risk model in NSCLC (E) Prognostic differences between high and low risk groups in the risk model (F) . Model risk scoring combined with clinical factors for univariate and multivariate COX analysis (G) . Comparison of immunotherapy effects between high and low risk groups of the risk model. (*P-value < 0.05; **P-value < 0.01, ***Pvalue < 0.001.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Expressing, Comparison

Journal: Frontiers in Oncology

Article Title: Long Non-Coding RNA AL513318.2 as ceRNA Binding to hsa-miR-26a-5p Upregulates SLC6A8 Expression and Predicts Poor Prognosis in Non-Small Lung Cancer

doi: 10.3389/fonc.2022.781903

Figure Lengend Snippet: Correlation analysis of SLC6A8 expression with immunomodulators.

Article Snippet: Slides were incubated for 1 hour at room temperature in 10 mM TBS with 4% normal rabbit serum (Proteintech) and incubated with primary antibody against SLC6A8 (1:50, 20299-1-AP, Proteintech Group, Inc, China) at 4°C overnight.

Techniques: Expressing